Literature DB >> 8878600

Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever.

D B Bethell1, N P Day, N M Dung, C McMullin, H T Loan, D T Tam, L T Minh, N T Linh, N Q Dung, H Vinh, A P MacGowan, L O White, N J White.   

Abstract

The pharmacokinetics of oral and intravenous ofloxacin (7.5 mg.kg of body weight-1 given over 30 min) were studied in an open crossover study of 17 Vietnamese children, aged between 5 and 14 years, with acute uncomplicated typhoid fever. Following oral administration, the median (95% confidence interval [CI]) time to peak concentration of ofloxacin in serum (Cmax) was 1.7 h (1.4 to 1.9 h) and the mean (95% CI) Cmax was 5.5 mg.liter-1 (4.7 to 6.3 mg.liter-1) compared with a Cmax of 8.7 mg.liter-1 (7.6 to 9.7 mg.liter-1) following the intravenous infusion. The median (95% CI) total apparent volume of distribution following the first intravenous dose, 1.35 liter.kg-1 (1.17 to 1.73 liter.kg-1), was significantly larger than that following the second dose, 0.99 liter.kg-1 (0.86 to 1.17 liter.kg-1; P < 0.0005), although the estimates for systemic clearance were similar: 0.255 liter.kg-1 h-1 (0.147 to 0.325 liter.kg-1 h-1) compared with 0.172 liter.kg-1 h-1 (0.127 to 0.292 liter.kg-1 h-1; P = 0.14). The mean residence times (95% CI) following intravenous and oral administration were similar: 5.24 h (4.84 to 6.58 h) and 6.24 h (5.32 to 7.85 h), respectively. The mean (95% CI) oral bioavailability was 91% (74 to 109%). The peak concentrations in serum were 10 to 100 times higher than the maximum MICs for ofloxacin against multidrug-resistant Salmonella typhi isolated in this area. Although the systemic clearance values were higher than those reported previously for adults, these data overall suggest that weight-or area-adjusted dose regimens for the treatment of typhoid in older children should be the same as those for adults.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878600      PMCID: PMC163492     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Penetration of ofloxacin from blood to sputum.

Authors:  B I Davies; F P Maesen; W H Geraedts; C Baur
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  JANA: a new iterative polyexponential curve stripping program.

Authors:  A Dunne
Journal:  Comput Methods Programs Biomed       Date:  1985-08       Impact factor: 5.428

3.  Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids.

Authors:  A Gough; N J Barsoum; L Mitchell; E J McGuire; F A de la Iglesia
Journal:  Toxicol Appl Pharmacol       Date:  1979-10       Impact factor: 4.219

4.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

5.  The effect of fever on antipyrine metabolism in children.

Authors:  J S Forsyth; T A Moreland; G W Rylance
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

6.  Glomerulitis in typhoid fever.

Authors:  V Sitprija; V Pipantanagul; V Boonpucknavig; S Boonpucknavig
Journal:  Ann Intern Med       Date:  1974-08       Impact factor: 25.391

7.  Effects on growth of single short courses of fluoroquinolones.

Authors:  D B Bethell; T T Hien; L T Phi; N P Day; H Vinh; N M Duong; N V Len; L V Chuong; N J White
Journal:  Arch Dis Child       Date:  1996-01       Impact factor: 3.791

8.  Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity.

Authors:  U B Schaad; J Wedgwood-Krucko
Journal:  Infection       Date:  1987 May-Jun       Impact factor: 3.553

Review 9.  Specific toxicologic aspects of the quinolones.

Authors:  W Christ; T Lehnert; B Ulbrich
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

Review 10.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

View more
  10 in total

1.  Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.

Authors:  S Thee; A J Garcia-Prats; H M McIlleron; L Wiesner; S Castel; J Norman; H R Draper; P L van der Merwe; A C Hesseling; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

2.  Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever.

Authors:  Christopher M Parry; Vo Anh Ho; Le Thi Phuong; Phan Van Be Bay; Mai Ngoc Lanh; Le Thanh Tung; Nguyen Thi Hong Tham; John Wain; Tran Tinh Hien; Jeremy J Farrar
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

Review 3.  Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections.

Authors:  John A Crump; Maria Sjölund-Karlsson; Melita A Gordon; Christopher M Parry
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

4.  Synergistic effect of ofloxacin and magnesium deficiency on joint cartilage in immature rats.

Authors:  Edith Lozo; Kai Riecke; Rudolf Schwabe; Jürgen Vormann; Ralf Stahlmann
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

5.  A comparative study of efficacy and safety of azithromycin and ofloxacin in uncomplicated typhoid Fever: a randomised, open labelled study.

Authors:  Manish Chandey; A S Multani
Journal:  J Clin Diagn Res       Date:  2012-08-25

6.  Typhoid sigmoid colon perforation in an 18-month-old boy.

Authors:  A Pandey; A N Gangopadhyay; V D Upadhyaya
Journal:  World J Pediatr       Date:  2008-12-23       Impact factor: 2.764

7.  Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.

Authors:  Anthony J Garcia-Prats; Heather R Draper; Stephanie Thee; Kelly E Dooley; Helen M McIlleron; James A Seddon; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

8.  Molecular typing of multiple-antibiotic-resistant Salmonella enterica serovar Typhi from Vietnam: application to acute and relapse cases of typhoid fever.

Authors:  J Wain; T T Hien; P Connerton; T Ali; C M Parry; N T Chinh; H Vinh; C X Phuong; V A Ho; T S Diep; J J Farrar; N J White; G Dougan
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

9.  The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy.

Authors:  Christopher M Parry; Ha Vinh; Nguyen Tran Chinh; John Wain; James I Campbell; Tran Tinh Hien; Jeremy J Farrar; Stephen Baker
Journal:  PLoS Negl Trop Dis       Date:  2011-06-21

Review 10.  Typhoid fever: issues in laboratory detection, treatment options & concerns in management in developing countries.

Authors:  Balaji Veeraraghavan; Agila K Pragasam; Yamuna D Bakthavatchalam; Ravikar Ralph
Journal:  Future Sci OA       Date:  2018-06-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.